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stenosis), and final kissing is not warranted. For multiple stenting, final kissing is
needed more often for culotte-stenting to achieve an optimal acute result. In the
presence of an optimal result after multiple stenting, final kissing did not seem to
provide additional benefit in our study.
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Impact of bifurcation type and stenting technique on outcome after unprotected
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Background: The optimal stenting technique for unprotected left main disease
(uLMCA) using drug-eluting stents (DES) is under debate, especially fpr true
bifurcation lesions.
Methods: This analysis is based on a randomized study. 607 patients with symptomatic
coronary artery disease undergoing percutaneous coronary intervention for uLMCA
were enrolled: 302 were assigned to receive a PES (Taxus, Boston Scientific) and 305
assigned to receive a SES (Cypher, Cordis). We evaluated the impact of bifurcation
type, number of stents, stenting technique and use of kissing balloon on the
angiographic restenosis rate (ISR) and the need of target lesion revascularisation (TLR)
at 6 months.
Results: 235 (39%) had a true bifurcation lesion (TBL, Medina 1,1,1). The presence
of TBL was associated with a higher need for multiple stents (60% vs. 19%, p<0.001).
The need for multiple stents was a significant predictor of ISR (30% vs. 10%, p<0.001),
with trend for TLR (13% vs. 8%, p=0.08), and the presence of TBL was a significant
predictor of ISR (27% vs. 12%, p<0.001) and for TLR (15% vs. 7%, p=0.003). After
correction for TBL, the need of multiple stents remained a significant predictor for
ISR (p≤0.01) but not for TLR (p≥0.58). Comparing techniques for multiple stenting,
culotte-stenting showed similar results compared to T-stenting for ISR (31% vs. 30%,
p=0.94) and for TLR (14% vs. 11%, p=0.80).
Conclusion: Treatment of uLMCA bifurcation lesions with DES is safe and effective.
The presence of true bifurcation lesions and need for multiple stents, but not the
stenting technique, were independent predictors for ISR. The only technical
independent predictor for TLR was a true bifurcation lesion.
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Background: Previous randomized trials have shown the superiority of everolimus-
eluting stent (EES) over paclitaxel-eluting stent (PES). No data exist about the
comparison of these two type of stents in unprotected left main disease (ULMD).
Methods: Prospective Florence registry of consecutive patients undergoing PCI for
ULMD. Patients receiving EES or PES for ULMD were included in the analysis. All
eligible patients were scheduled for 6 month angiographic follow-up. A propensity
score-matched analysis (1:1) was also performed because of the expected differences
in baseline characteristics between patients receiving EES and patients receiving PES.
Primary end point: 6-month angiographic in-segment binary restenosis > 50%. Logistic
regression analysis was used to test independent predictors of left main in-stent
restenosis.
Results: From January 2004 to December 2010, 357 patients received EES or PES
implantation for ULMD (n=134 had EES and n=223 had PES). EES and PES group
were different in several baseline characteristics: renal insufficiency 10% vs 21% (p =
0.004), stable angina 38% vs 19% (p=0.008), peripheral vascular disease 19% vs 32%
(p = 0.008) and EUROscore ≥ 13 was 36% vs 24% (p= 0.014). The 6-month
angiographic follow-up rate was 98% and binary restenosis rate was 5.6 % in EES vs
15.8% in PES group (p= 0.006). At multivariable analysis EES was the only
independent predictor of binary restenosis (OR 0. 33, 95% CI 0.14-0.76; p = 0.010).
After propensity score-matched analysis the two groups were well balanced (n=134
EES, n=134 PES patients) and binary restenosis rate remains significantly lower in
EES group as compared to PES group (5.7% vs 15.9%, p = 0.010).
Conclusion: This study confirms the superiority of EES in the subset of patients with
ULMD. EES in ULMD is associated with a very low rate of restenosis and it is the
only independent predictor of angiographic restenosis rate.
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Background: Limited long-term outcome data is available to support the use of drug-
eluting stents in the treatment of unprotected left main (LM) coronary artery disease.
Methods: In this multicenter registry, 291 patients with a mean age of 68.9±11.2yrs,
with unprotected LM stenosis underwent percutaneous revascularization with
paclitaxel-eluting stents (PES), using a consistent technical approach for both
ostial/shaft and bifurcation lesions (provisional side-branch stenting). This 5-year
follow-up study focuses on the incidence of device driven major adverse cardiovascular
events (MACE), defined as the composite of cardiac death, myocardial infarction (MI),
and target lesion revascularization (TLR).
Results: At 5 years (n=263), the cumulative incidence of MACE was 23.6%, and the
rates of all-cause and cardiac death were 24.3% and 12.5% respectively. During follow-
up, MI occurred in 16 patients (6.1%) and the incidence of TLR was 10.3%. Definite
stent thrombosis occurred in 0.4%. There was no significant difference in outcomes
between patients with ostial/shaft or bifurcation lesions, although a trend towards
increased TLR in distal lesions was observed (11.6%vs5.3%,p=0.22). In contrast,
patients with distal LM lesions requiring two-stent procedures had a higher rate of
MACE than patients with one-stent interventions (34.1%vs17.8%,p=0.009). This was
driven by an increased incidence of cardiac death (18.2%vs8.5%,p=0.05) and non-Q-
wave MI (8.0%vs1.7%,p=0.04) in the two-stent cohort. At 5 years, the incidence of
MACE was significantly higher in diabetic patients compared to nondiabetic subjects
(32.9%vs20.0%,p=0.03). This difference was primarily driven by an increase in TLR
in diabetic patients (19.2%vs6.8%,p=0.005).
Conclusion: These long-term results show that the treatment of unprotected LM
stenosis with PES is safe and efficacious. Outcomes are similar for ostial/shaft and
distal LM interventions, however one-stent interventions should be the preferred
strategy for distal LM lesions.
TCT-45
The ESTROFA-LM Registry: Comparison of Taxus and Xience Stents in Left
Main Coronary Artery Disease. Preliminary Results at 3 Years Follow-up
Jose M De la Torre Hernandez1, Angel Sanchez Recalde2, Bruno Garcia del Blanco3,
Neus Salvatella4, Tamara Garcia Camarero1, Felipe Hernandez6, Fernando Rivero5,
Jose Moreu7, Jose R Rumoroso12, Francisco Bosa8, Monica Masotti9, Juan A
Bullones10, Jesus Jimenez Mazuecos11
1Hemodinamica, Hospital U. Marques de Valdecilla, Santander, Spain; 2Hospital La
Paz, Madrid, Spain; 3Hospital Vall de Hebron, Barcelona, Spain; 4Hospital
Bellvitge, Barcelona, Spain; 5Hospital La Princesa, Madrid, Spain; 6Hospital 12 de
Octubre, Madrid, Spain; 7Hospital Virgen de la Salud, Toledo, Spain; 8Hospital
Clinico de Tenerife, Santa Cruz de Tenerife, Spain; 9Hospital Clinic, Barcelona,
Spain; 10Hospital Carlos Haya, Malaga, Spain; 11Hospital de Albacete, Albacete,
Spain; 12Hospital de Galdacano, Bilbao, Spain
Background: The evidences of therapy with drug-eluting stents (DES) in the left main
coronary artery are mostly based on trials performed with first-generation DES. There
is paucity of data with long-term follow up with second-generation DES in this setting.
Methods: The ESTROFA-LM is a multicenter retrospective registry collecting
consecutive patients treated in unprotected left main coronary artery with a first-
generation DES (Taxus) and with a second-generation DES (Xience V).
Results: The registry is still open and 11 centers have provided data so far. Up to now
304 pts have been included, 164 treated with Taxus and 140 treated with Xience. The
clinical and angiographic characteristics were comparable in both groups with a trend
for more diabetes in Xience group (33.3% vs 44.3%;p=0.06). PCI in other vessel was
equivalent (68.3% in Taxus and 69.3% in Xience). The 3 years survival free of death
and infarction was 84.4% for Taxus and 85.4% for Xience (p=0.9). Definite or probable
thrombosis was 1.2% for Taxus and 0.7% for Xience (p=0.8). At 3 years the incidence
of target lesion revascularization was 2.4% for Taxus and 2.8% for Xience (p=0.8).
Conclusion: The preliminary results of this multicenter registry suggest a comparable
safety and efficacy at 3 years for Taxus and Xience in the treatment of the left main
coronary artery. A large additional enrollment is expected in following months.
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